Cite
HARVARD Citation
Goldman, J. et al. (2020). Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung cancer. pp. 46-52. [Online].